2Suppliers
2Customers
2Debt Items
3Related Chains

NanoViricides, Inc. Suppliers

TickerNameConfidenceEvidence
D-BORAL-CAPITAL-LLC D-BORAL-CAPITAL-LLC 92% The Company entered into a Placement Agency Agreement with D. Boral Capital LLC (the “Placement Agent”), dated May 15, 2026, pursuant to which the Placement Agent acted as the exclusive placement age…
THERACOUR THERACOUR 92% Further, the Company has subcontracted nanomaterials research and development ("R&D") to TheraCour under the license agreement with TheraCour.

NanoViricides, Inc. Customers

TickerNameConfidenceEvidence
THERACOUR THERACOUR 90% We will develop these drugs in part via subcontracts to TheraCour, the exclusive source for these nanomaterials.
EF-HUTTON-LLC EF-HUTTON-LLC 62% ion, NanoViricides will pay 15 % of net sales to TheraCour, as defined in the agreement. ​ On March 27, 2023 the Company entered into a license agreement with KMPL wherein the Company granted to KMPL…

NanoViricides, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
NNVC-DEBT-11327 Warrants outstanding: 347222 90% xbrl warrant detail from xbrl 2020-01-27.
NNVC-DEBT-11328 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-06-30.

NanoViricides, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for NanoViricides, Inc..

NanoViricides, Inc. Ownership

HolderNameConfidenceEvidence
NNVC-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 49 tracked holders.

NanoViricides, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
OKYO OKYO Pharma Limited 100.00 2
TLSA Tiziana Life Sciences Ltd 50.00 2
SIGA SIGA Technologies, Inc. 38.88 1 ['receiving']